Rare Haematology Market Size, Share and Forecast to 2026
Globally, the Rare Hematology market was estimated at USD XX billion in 2018 and is expected to reach USD XX billion by 2026. The market is large and growing primarily led by Hemophilia.
(EMAILWIRE.COM, September 09, 2019 ) Market Overview:
Rare hematological diseases fall into many subcategories, including anemia-type red blood cell conditions, white blood cell dysfunctions associated with various malignancies, immuno-disorders, platelet-based abnormalities that affect coagulation, and plasma-based issues (such as hemophilia A and B, von Willebrand disease).
Globally, the Rare Hematology market was estimated at USD XX billion in 2018 and is expected to reach USD XX billion by 2026. The market is large and growing primarily led by Hemophilia.
Market Dynamics:
Global incidence of hemophilia is not well known, but it is estimated that more than 400,000 people are living with hemophilia A and B. However, there is still a substantial unmet need for new therapies that require significantly less frequent infusions and do not promote inhibitor formation.
Market Segmentation:
By Product Class
• Recombinant factor
• Plasma-derived factors
• Extended Half-Life
By Indication
• Hemophilia A
• Hemophilia A with Inhibitors
• Hemophilia B
• Acquired Hemophilia A
• Von Willebrand disease
By Patient Age-group
• Pediatrics (0-17)
• Adults (18+)
Geographical Analysis:
By Geography, the market is segmented into:
• Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)
• Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)
• North America (The USA, Canada, Mexico)
• South America (Brazil, Argentina, Rest of South America)
• The Middle East and Africa
Competitive Analysis:
Key Players:
• Biogen Inc.
• Shire plc
• Bayer Healthcare AG
• Novo Nordisk A/S
• Pfizer Inc.
• CSL Behring LLC
View full report: https://www.datamintelligence.com/research-report/rare-haematology-market
Download free sample: https://www.datamintelligence.com/download-sample/rare-haematology-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
Rare hematological diseases fall into many subcategories, including anemia-type red blood cell conditions, white blood cell dysfunctions associated with various malignancies, immuno-disorders, platelet-based abnormalities that affect coagulation, and plasma-based issues (such as hemophilia A and B, von Willebrand disease).
Globally, the Rare Hematology market was estimated at USD XX billion in 2018 and is expected to reach USD XX billion by 2026. The market is large and growing primarily led by Hemophilia.
Market Dynamics:
Global incidence of hemophilia is not well known, but it is estimated that more than 400,000 people are living with hemophilia A and B. However, there is still a substantial unmet need for new therapies that require significantly less frequent infusions and do not promote inhibitor formation.
Market Segmentation:
By Product Class
• Recombinant factor
• Plasma-derived factors
• Extended Half-Life
By Indication
• Hemophilia A
• Hemophilia A with Inhibitors
• Hemophilia B
• Acquired Hemophilia A
• Von Willebrand disease
By Patient Age-group
• Pediatrics (0-17)
• Adults (18+)
Geographical Analysis:
By Geography, the market is segmented into:
• Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)
• Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)
• North America (The USA, Canada, Mexico)
• South America (Brazil, Argentina, Rest of South America)
• The Middle East and Africa
Competitive Analysis:
Key Players:
• Biogen Inc.
• Shire plc
• Bayer Healthcare AG
• Novo Nordisk A/S
• Pfizer Inc.
• CSL Behring LLC
View full report: https://www.datamintelligence.com/research-report/rare-haematology-market
Download free sample: https://www.datamintelligence.com/download-sample/rare-haematology-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
Contact Information:
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results